LADX — LadRx Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
Brief: CytRx announces positive phase 2B trial results for soft tissue sarcoma
Brief: CytRx announces the presentation of its phase 2b clinical trial design in small cell lung cancer
Brief: CytRx prices public offering of 9.1 million shares of common stock
Brief: CytRx announces proposed public offering of common stock
Brief: CytRx announces presentation of interim phase 2 data for Aldoxorubicin for HIV-Related Kaposi's Sarcoma
Brief: CytRx announces settlement of stockholder derivative lawsuit in Delaware
Brief: CytRx's aldoxorubicin continues to show no clinically significant cardiac toxicity
Brief: CytRx reports positive updated Phase 2 Aldoxorubicin clinical trial results in glioblastoma multiforme
Brief: CytRx says announced interim analysis from two ongoing phase 1b Aldoxorubicin combination studies
Brief: CytRx reports Q1 loss per share $0.31
Brief: CytRx announces overall survival results from phase 2b clinical trial of Aldoxorubicin
Brief: CytRx announces FDA's removal of partial clinical hold for Aldoxorubicin clinical trials
CytRx cancer drug shows promise in mid-stage study
Brief: CytRx announces positive interim mis-stage aldoxorubicin results as a treatment for hiv-related kaposi's sarcoma
CytRx says FDA to decide on study enrollments in January (updated)
Brief: CytRx CEO cautiously optimistic about FDA's pending decision on lifting partial clinical hold on trials
US STOCKS-Wall St flat after biggest selloff in three months
Cytrx cancer drug shows promise in mid-stage study
Brief: CytRx announces positive interim phase 2 aldoxorubicin results in glioblastoma multiforme